In eukaryotes, mRNA abundance is often a poor proxy for protein abundance [1] [2] [3] [4] [5] . Despite this, the majority of methods used to dissect function in mammalian biology 6 and for biomarker discovery in complex diseases 7 involve manipulation or measurement of mRNA. The discrepancy between mRNA and protein abundance is likely due to several factors, including differences in the rates of translation and degradation between proteins and cell-types 8 , unequal contribution of individual splice variants to the production of a given protein 9 and cell-type specific differences in splice variant use 10 . Here we performed experimental and computational time-series analysis of RNA-seq and mass-spectrometry of three key immune cell-types in human and mice and constructed mathematical mixed time-delayed splice variant models to predict protein abundances. These models had median correlations to protein abundance measurements of 0.79-0.94, which is a significant increase from the previously reported 0.21 on human protein atlas data 1 , and out-performed less complicated models without the usage of multiple splice variants and time-delay in cross-validation tests. We showed the importance of our models for biomarker discovery by re-analysing RNA-seq data from five different complex diseases, which led to the prediction of new disease proteins that were validated in multiple sclerosis. Our findings suggest that similar protein abundance models may be created for the most critical cell-types in the human body.
To understand the effect of splice-variant selection and translation rate on the relationship between RNA and protein abundance, we performed RNA-sequencing and mass-spectrometry proteomics of primary human naïve CD4 + T helper (NTH) cells at six time points during differentiation into T-helper type 1 (TH1) cells ( Figure 1A , S1, S2). TH1 differentiation is an optimal model system to dissect the relationship between mRNA and protein as (i) primary human NTH cells can be isolated in high purity and large quantity from human blood (ii), all NTH cells are synchronised in the G1 phase of the cell cycle, further reducing inter-cell heterogeneity 11, 12 and (iii) changes in mRNA and associated protein abundance can be assayed over time 13 . Moreover, T helper cells are important regulators of immunity and thereby associated with many complex diseases, and TH1 differentiation itself is pathogenetically relevant in several diseases 14, 15 .
Interestingly, although the majority of genes showed a significant positive correlation between mRNA level and protein level (n=407, expected 123 out of 4920 proteins, binomial test P<10 we used data from the human protein atlas 20 . We found that this only resulted in marginal improvements in correlation with respect to that previously reported in the literature 1 (rhoProtAtlas= 0.27), see ( Figure S3 ). This lack of correlation can be explained by the lack of dynamic data, and by the presence of different cell types. In further support of cell type specificity, we found only marginal correlations (rho = 0.09) when comparing the correlation coefficients of our two T-cell data-sets of TH1and Treg cells. Thus, a common unifying model for many cell-types remains a challenge (Data S1). In summary, we have revealed that using a simple linear model of mRNA splice variants and time delay, we could predict protein abundances accurately.
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The copyright holder for this preprint . http://dx.doi.org/10.1101/599373 doi: bioRxiv preprint first posted online Apr. 4, 2019; To test the clinical usefulness of our results, we applied our model to available RNA-sequencing data-sets involving TH-associated diseases. Using data derived from human total CD4 + T cells in asthma, allergic rhinitis, obesity-induced asthma, pro-lymphocytic leukaemia, and multiple sclerosis (MS), we found for each disease a higher fraction of nominally differentially expressed proteins than standard differential expression analysis (Figure 2A) . For MS, the TH1 model resulted in the highest fraction and 21 proteins were predicted as differentially expressed at FDR<0.05, whereof three (Annexin A1, sCD40L and sCD27) were annotated as extracellular according to gene ontology. To validate these predictions, we analysed if cerebrospinal fluid (CSF) levels of these proteins related to clinical outcome and immunomodulatory treatment in two independent cohorts, namely newly diagnosed MS (clinically isolated syndrome (CIS) and relapsing/remitting MS, n=41) vs healthy controls (HC, n=23), and response to Natalizumab treatment in relapsing remitting MS patients (see Methods, n=16). In both cohorts, only sCD27 was present at a detectable level. Analysis of all patients (n=57) vs HC (n=23) showed high separation (AUC=0.88, non-parametric P=3.0 x 10 -8 , Figure 2B ), and treatment with Natalizumab reduced the sCD27 levels by 34% (P = 4.9 x 10 -4 ). Lastly, we tested the prognostic value of sCD27 and found that the baseline levels in the newly diagnosed MS patients were able to predict disease activity after four years follow up (AUC= 0.87, P=1.2 x 10 -3 , Figure 2B ), which was stronger than that of all our previously reported 14 biomarkers 21 . Taken together, the high correlation between predicted and measured protein levels from mass-spectrometry, the increased fraction of differentially expressed predicted proteins and successful biomarker validation, show the relevance of our CD4 + T cell models for discovery of protein biomarkers in TH-cell mediated diseases from RNA-seq data alone.
In conclusion, we have shown that simple mRNA-protein models, in which the protein expression is defined as a linear combination of the splice variants of a gene, with a time-delay accounting for the dynamical effect induced by post-transcriptional processes and protein synthesis, can profoundly improve our ability to predict protein abundance from mRNA abundance. We expect this modelling strategy to be generally applicable to other cellular differentiation systems, such as embryonic stem cell differentiation, and to be increasingly useful for understanding basic biology and identification of new biomarkers as more RNA-seq and proteomic data sets become publicly available.
. 
Material and methods

Experimental protocol
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Bioinformatics: All RNA-seq data were processed similarly using the following pipeline.
Sample qualities were assessed with fastQC and the mRNA reads were subsequently aligned using STAR 22 to the "Homo_sapiens.GRCh37.75.dna.primary_assembly.fa" from Ensemble. 
Splice variant model construction:
We trained a linear regression model with a LASSO constraint model using the python package Sklearn 25 . We implemented a time-delay shift which was defined using a grid of 195 values, exponentially increasing from 0 to 24h. Linear interpolation was used to estimate the corresponding protein values. Specifically, for different we solve the following:
Here, the time series of one protein is denoted by the vector Y, and the corresponding time series of the splice variants are denoted by the matrix X. The λ term was chosen to minimize the prediction error of a leave-one-out cross validation. For each τ, we did a leave-one-out cross validation on top of the one used for determining the λ parameter. Next, the τ yielding the lowest error on an outer cross validation error was selected. Testing for τ=0 was used when studying the information gain from combining splice variants. Pipe-line and code available from https://gitlab.com/Gustafsson-lab/IMUNA-an-integrated-multilevel-Th1-analysis .
Disease prediction
Disease relevance of the splice variant models was tested by re-analysis of deep RNAsequenced case control material of samples containing total CD4 + T-cells, i.e. CD4 + T-cells with all its sub-types. We found T-cell prolymphocytic leukemia (T-PLL, GSE100882), asthma in obese children (GSE86430), and allergic rhinitis/asthma (GSE75011) studies through a Gene Expression Omnibus (GEO) repository search and multiple sclerosis (MS) through collaboration 26 . For each of the studies' datasets, we used the TH1 and Treg derived models on how to combine mRNA splice variants to predict protein abundance. The resulting sets of predicted protein levels were tested for differential expression between patients and controls using a non-parametric Kruskal-Wallis test. We also applied Kruskal-Wallis tests to the individual splice variants that were used by the models. We assessed model effects by . CC-BY 4.0 International license It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint . http://dx.doi.org/10.1101/599373 doi: bioRxiv preprint first posted online Apr. 4, 2019; measuring the increase in nominally differential expression from model predictions compared to ingoing splice variants into the model.
Protein validation
Three of the DEPPs (Annexin A1, sCD40L and sCD27) were measured in cerebrospinal fluid (CSF) from two different cohorts, one with of 41 patients with newly diagnosed MS and 23 healthy matched controls (Supplemental table) 
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